[Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial].

Xiaoyan Ge, Linhua Yang, Jie Jin, Wenbin Qian, Jianyong Li, Renchi Yang, Xiang-shan Cao, Bin Jiang, Zhao Wang, Ming‐Feng Hou, Weihua Zhang, Zhongping Xiao, Yongqiang Zhao, Da Gao, Xiaohong Zhang, Shuye Wang, Aining Sun, Jinxiang Fu, Li Su, Kang LiPubMed 2015 · DOI

Abstract

Anagrelide was effective in patients with ET which had similar hematologic remission rate to hydroxyurea and could take effect more quickly than hydroxyurea. Incidence of adverse events was undifferentiated between anagrelide and hydroxyurea, but anagrelide treatment had tolerable adverse effects and no hematologic toxicity.
BibTeX
@inproceedings{ge2015efficacy,
  author = {Xiaoyan Ge and Linhua Yang and Jie Jin and Wenbin Qian and Jianyong Li and Renchi Yang and Xiang-shan Cao and Bin Jiang and Zhao Wang and Ming‐Feng Hou and Weihua Zhang and Zhongping Xiao and Yongqiang Zhao and Da Gao and Xiaohong Zhang and Shuye Wang and Aining Sun and Jinxiang Fu and Li Su and Kang Li},
  title = {{[Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial].}},
  booktitle = {PubMed},
  year = {2015},
  doi = {10.3760/cma.j.issn.0253-2727.2015.07.00},
}

Loading related content...

Figure